Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa and a Multi-Pronged
Approach to Combat its Infection in Veterinary Science and Public Health: A Review
Bahar-e-Mustafa1,
Muhammad Adnan Ashraf2*, Muhammad Khalid Bashir3,4 and
Hira Batool5
1University
of Agriculture, Faisalabad. Sub-Campus Toba Tek Singh, Pakistan
2Institute
of Microbiology, University of Veterinary and Animal Sciences, Lahore, Pakistan
3Animal
Breeding and genetics, University of Agriculture, Faisalabad
4Directorate
of Graduate Studies, University of Agriculture, Faisalabad
5Chughtai
Lab, 10 Jail Road, Main Gulberg, Lahore Pakistan
*For correspondence: adnan.ashraf@uvas.edu.pk
Received
13 January 2021; Accepted 27 March 2021; Published 10 June 2021
Abstract
Pseudomonas
aeruginosa is one of the most important nosocomial pathogens
associated with a variety of medical and veterinary infections and therefore,
it presents a major public health threat. Different classes of antibiotics are
being used to treat its infections which are increasing selective pressure to
multi-drug resistance development. Resistance to antibiotics in P. aeruginosa is due to many of the
common and unique mechanisms which include: reducing membrane permeability,
modification or inactivation of antibiotics, alteration of enzymes,
modification of target sites and over-expression of efflux systems. Over or
under expression of the genes of porin channels and components of efflux
systems play a major role in the resistance mechanisms of P. aeruginosa. To overcome the problem of the emergence of
antibiotic resistance, many new strategies are being employed to control
infections caused by P. aeruginosa.
These include the use of herbs/medicinal plants and phage therapy. With the
advent of modern technology, the molecular mechanisms of these alternative
therapies are being elucidated and may be used in future to treat P.
aeruginosa infections in humans and veterinary clinics. This review
thus highlights the mechanisms of antibiotic resistance of P. aeruginosa against the commonly used antimicrobials and also
some alternative strategies to control P.
aeruginosa infection. © 2021 Friends Science Publishers
Keywords: Pseudomonas;
Antibiotic resistance; Efflux pump; Disinfectant; Porin
Introduction
Antimicrobial therapy has remained beneficial in
treating infectious diseases caused by bacteria. During exposure to
antibiotics, pathogens have developed resistance and have become a challenge
for healthcare professionals. Among Gram-negative bacteria, Escherichia coli, Acinetobacter baumanni and Klebsiella pneumoniae have become resistant to many antibiotics
but the most important pathogen which has shown resistance to all classes of
antibiotics is Pseudomonas aeruginosa (P. aeruginosa) (Breidenstein et al. 2011). The
organism is a gram-negative;
motile bacterium that lacks fermentative properties (which differentiates it
from Enterobacteriaceae). It can grow
in harsh conditions with low levels of nutrients, bearing the temperature range
from 4ºC to 44ºC. It is an opportunistic microorganism, which is associated
with a variety of infections including cystitis, pneumonitis, gastritis, otitis
and keratitis in immunocompromised individuals. It is not present in normal
human microflora, but it is one of the most notorious organisms responsible for
nosocomial infections. It colonizes moist places in hospitals including benchtop
surfaces, surgical instruments, urinary catheters and intravenous catheters. P. aeruginosa can survive in
disinfectants, making it unique as compared to other pathogens (Chakraborty et al. 2016). Chances of
its infection increase with the increase in time of hospitalization (Ferstl et al. 2016).
A variety of factors play roles in the pathogenesis of P. aeruginosa including virulence factors. Factors associated
with its surface are lipopolysaccharide, rhamnolipids, flagella, mucus and
fimbriae, while enzymatic virulence factors include alkaline protease,
elastase, hemolysin, neuraminidase, gelatinase, and phospholipases (van ‘t Wout et al. 2015). These virulence
factors help in evading the human immune system and establishing the infection (Khalil et al. 2015). Mechanisms of its
resistance are intrinsic as well as extrinsic, depending upon the nature of
genes involved. Intrinsic mechanisms involve genes from its chromosome while
acquired resistance can be obtained from plasmids or bacteriophages, by
horizontal gene transfer. Infections of P.
aeruginosa are difficult to control due to its wide variety of virulence
factors and resistance mechanisms. In this review, we highlight the resistance mechanisms
against different antibiotics. Understanding of these mechanisms will help in
the judicious use of antibiotics and the study of new ways to control this
pathogen.
Mechanisms of
antibiotic resistance
All antimicrobials must penetrate the cell wall of a
bacterium to be effective. Pseudomonas
aeruginosa is resistant to a variety of antibiotics, primarily because it
offers limited entry to different antimicrobials. It has a polysaccharide
barrier (alginate) around it, which is anionic and can effectively bind with
the cationic antimicrobials e.g.
aminoglycosides and restricts their entry into the cell (Germoni et al. 2016). Moreover, the outer membrane of P. aeruginosa also acts as a major
barrier in the passage of different molecules which are larger and hydrophilic
in nature. Hydrophilic antimicrobials of small molecular size can easily cross
the outer membrane of the bacteria by passage through porins (Song et al. 2015).
Decreasing permeability
Outer membranes of Gram-negative bacteria contain heavy
outer membrane proteins in them. These proteins are porin channel i.e.,
oprJ, oprN, oprM, oprN which help in the transport of molecules but resist the
antimicrobials physically or in combination with active efflux pumps. Pseudomonas aeruginosa provides less
membrane permeability to antimicrobials as compared to the members of Enterobacteriaceae due to the high ratio
of porins. Porin proteins and efflux pumps work side by side to increase their
resistance. oprF is a major type of porin produced by all strains of the P. aeruginosa. OprD is another important
porin involved principally in the uptake of lysine (and other positively
charged amino acids). If this porin is lost, it results in the resistance to
the meropenem (Fluit et al. 2019)
and carbapenem (Richardot et al. 2015).
Another porin is OprH which prevents the binding of antimicrobials to the
lipopolysaccharides (LPS) of bacteria thus preventing the uptake of those
compounds (Qadi et al. 2016).
Efflux system
(multidrug)
Different
families of efflux system are the protein pumps involved in resistance for the
transport of substances across the bacterial membrane and cell wall. One of the
families is resistance-nodulation-division (RND) which characterizes both
impermeability resistance and adaptive resistance to multiple antibiotics in P. aeruginosa. It is primarily composed
of three major components that include 1) an inner membrane pump (the RND
component), 2) An outer membrane channel-forming porin and 3) a periplasmic
linker protein which joins the two components together (Fig. 1A, B, C, D).
While writing the name of the efflux pump, periplasmic linker and the inner
membrane pump come first followed by the type of porin (Daury et al. 2016). Different types of efflux systems which
are reported for the P. aeruginosa are
mexAB-oprM (mexA = periplasmic linker, mexB = membrane pump, oprM = porin),
mexCD-oprJ, mexEF-oprN, mexXY-oprM and mexXY-oprN. The most commonly present
efflux pump is the mexAB-oprM while mexXY-oprN is less commonly found. The
activity of mexXY-oprN is dependent on the presence or absence of porin oprD,
as its range of resistance is increased with the absence of oprD
porin (Kao et al. 2016). Common
types of efflux pumps are mentioned in Table 1.
Table 1: Common types of multi-drug resistance efflux pumps with their resistant
and susceptible antibiotics
Periplasmic Linker |
Inner membrane Pump |
Porin |
Resistance to Antimicrobials |
Antimicrobials not affected |
MexA |
MexB |
OprM |
Quinolone, Macrolide, Tetracycline, Chloramphenicol,
anti-pseudomonal Penicillins, anti-pseudomonal Cephalosporins,
Disinfectants |
Aminoglycoside, Imipenem |
MexC |
MexD |
OprJ |
Quinolone, Macrolide, Tetracycline, Chloramphenicol, |
Carbenicillin, Sulbenicillin,
Ceftazidime |
MexE |
MexF |
OprN |
Fluoroquinolone, Chloramphenicol, Trimethoprim,
Carbapenems |
Ticarcillin, Cefepime, Aztreonam, Aminoglycoside |
MexX |
MexY |
OprM |
Quinolone, Macrolide, Tetracycline, Chloramphenicol,
β-lactams, Aminoglycosides |
Carbenicillin, Sulbenicillin,
Cefsulodin, Ceftazidime |
MexAB-OprM efflux system participates in both
intrinsic as well as acquired resistance in P.
aeruginosa, but MexEF-OprN and MexCD-OprJ contribute only to the acquired
resistance. Role of these efflux pumps was
Fig. 1: A; Periplasmic linker protein, B; Inner
membrane pump, C; Channel porin, D; Complete Efflux pump
confirmed
by the knock-out gene mutations. At the start, oprK was considered to be the
porin channel of MexAB efflux pump and was referred as MexAB-oprK pump but later on, oprM was found to be the porin
of MexAB efflux pump and named as MexAB-oprM efflux
pump (Baranova 2016). Moreover, the
efflux system also plays an important role in inducing resistance against
meropenem (Rostami et al. 2018).
Modification
and inactivation of antibiotics
The AmpC gene is possessed by all Pseudomonas strains. This gene primarily produces resistance to
beta-lactam antibiotics. AmpR is a regulatory gene which is responsible for the
overproduction of beta-lactamase by P.
aeruginosa strains. Beta-lactamase is present in the periplasmic space of P. aeruginosa. Beta-lactamases, as well
as integron and plasmid-encoded extended-spectrum beta-lactamases (ESBLs), are
responsible for contributing resistance against cephalosporin and penicillin.
Beta-lactamase inhibitors interfere with the enzyme by plasmid but not by AmpC gene (Buberg et al.
2020).
In the case of P.
aeruginosa, this mechanism has been observed against quinolones and
penicillins. Quinolones bind to DNA gyrase enzyme. A gyrA mutation results in the change of the DNA gyrase enzyme, thus
making quinolones ineffective (Park et al.
2020). Pseudomonas strains
associated with cystic fibrosis exhibit
a frequent change in the penicillin-binding proteins (PBP’s) resulting in the resistance
against the penicillin group. mRNA expression levels of oprM and ampC genes led
to 21.7 and 25% resistance respectively. Point mutation of AmpR at Asp135-Asn
and Als194-Ser deregulated the ampC induction and led to 21.7% resistance in Pseudomonas isolates (Du et al. 2010).
Induction of biofilm
Pseudomonas
aeruginosa colonization appears as the aggregate of the cells,
surrounded by the protective coating of polysaccharide, alginate, proteins and
extracellular DNA. These biofilms are becoming a major source of resistance
against antibiotics and disinfectants (Hameed et
al. 2017). Pseudomonas
aeruginosa effectively forms biofilms when exposed to the sub-optimal
concentrations of the different antibiotics like tobramycin, tetracycline and
ciprofloxacin. Tobramycin is also responsible for the induction of swimming and
swarming in P. aeruginosa (Linares et al. 2006). Biofilm resists
by interacting with different mechanisms simultaneously. Biofilm matrix allows
limited penetration of antibiotics towards bacterial cells. Bacterial cells
produce a limited number of inactive cells in the biofilm matrix that do not
grow or die even in the presence of antibiotics, called persister cells. These
cells have the special ability to tolerate multiple antibiotics after their
diffusion through the matrix (Dawson et al.
2011). Extracellular DNA having negative charge binds with the cationic
antimicrobial peptides including polymyxin to restrict their entry into the
cell. Moreover, exposure of pseudomonal biofilms to the imipenem resulted in
enhanced expression of genes responsible for the biosynthesis of alginate,
which results in the production of stronger biofilm formation (Olivares et al. 2020).
Resistance
against beta-lactam ring containing antibiotics
P. aeruginosa is resistant against many compounds which may be
structurally related or unrelated. Intrinsically, it is resistant to many
antimicrobial compounds due to β lactamases against penicillin G,
aminopenicillins and cephalosporins. Beta-lactam antibiotics lead to induction
of the AmpC gene which is chromosomally encoded but horizontal gene transfer
increases resistance as well. The incidence of ESβL resistant strains
between P. aeruginosa isolates was
found 26.86 and 25.14% in nosocomial and community sources, respectively (Sahu et al. 2012). Moreover, 25.3 and
28.7% P. aeruginosa isolates were
resistant to meropenem and imipenem (Hu et
al. 2017). The resistance is due to outer membrane permeability and
efflux pumps (transporters) that actively push beta-lactam antibiotics out of
the cell and also got the ability to contain some of the enzymes which can
inactivate the antimicrobial drugs e.g., penicillinases and
cephalosporinases (Xu et al. 2020).
Carbapenems are considered as last resort antibiotics for the treatment of P. aeruginosa along with colistin (Manohar et al. 2018).
Induction of AmpC gene and the
extent of hydrolysis of antibiotics decide the fate of beta-lactams against P. aeruginosa. Amoxicillin, 1st
and 2nd generation cephalosporins are relatively ineffective against
P. aeruginosa infections due to their
easy hydrolysis and strong induction of AmpC. An important group of beta-lactam
antibiotics that are used to treat the infection of P. aeruginosa include ureidopenicillins (azlocillin),
carboxypenicillins (ticarcillin and carbenicillin), 3rd & 4th
generation cephalosporins (ceftazidime and cefoperazone), aztreonams and
carbapenems (meropenem and imipenem) (Bagge et
al. 2002). This is leading to the appearance of new
β-lactamases by natural evolution.
Aminoglycosides
Aminoglycosides are bactericidal and they do this by
binding to the 30S subunit of bacterial ribosomes, misreading of the codons and
thus causing the death of microorganisms (Dunkle
et al. 2014). Pseudomonas
aeruginosa is naturally resistant to some of the aminoglycosides
like kanamycin because it can easily phosphorylate it (Kondo and Hotta 1999). The uptake of the aminoglycosides is a
complex process which involves binding with LPS and permeability offered by the
outer membrane of Gram-negative bacteria, then crossing of substances across
the plasma membrane due to action potential and ultimately binding with
ribosomes and disrupting the polypeptide synthesis in bacteria (Krahn et al. 2012). Pseudomonas aeruginosa has developed
resistance which causes methylation of nucleotides due to horizontal gene
transfer.
Strains of P.
aeruginosa isolated from the clinical and laboratory studies have shown
both intrinsic and adaptive type of resistance against aminoglycosides. It is
well documented that aminoglycosides can also be
antagonized by certain ions of divalent nature i.e., Ca and Mg particularly
in the case of P. aeruginosa (Morita et al. 2012). A recent analysis at the transcriptomic level has shown that
aminoglycosides can affect the variety of the genes of intrinsic and adaptive
nature. Pseudomonas aeruginosa, when
exposed to the tobramycin for quite a prolonged interval of time at a dose less
than MIC can significantly enhance the expression of MexXY (efflux pump) genes.
Heat shock genes (i.e., groES, asrA, htpG and ibpA) are also
overexpressed when P. aeruginosa is
exposed to tobramycin at a sub-lethal concentration; among them, asrA is
particularly important regarding resistance to aminoglycosides (Basta et al. 2020). Expression of
chromosomal genes mexZ, rplY, PA5471, nuoG & galU, and MexXY–OprM efflux
system increase aminoglycoside resistance in P. aeruginosa (Islam et al.
2009).
Resistance
against tetracycline
Tetracycline group is primarily bacteriostatic in action
and includes a variety of antimicrobial compounds. An energy-driven process is
required to enter the tetracyclines inside the cell, where they bind to the 30S
ribosomal subunit and interfere with the binding of aminoacyl-tRNA to the A
site (acceptor) in the ribosomal-RNA complex. Intrinsically tetracyclines are
ineffective against Pseudomonal infections because of the presence of the
MexAB/mexXY multidrug efflux type of pumps (Konai
and Haldar 2020).
Resistance
against macrolides
Macrolides are a group of antimicrobials that also tend
to interfere with the synthesis of proteins in microorganisms and they do this
by attaching to the 50S subunit of ribosomes. These are commonly used to treat
the pulmonary infections associated with P.
aeruginosa (Laserna et al. 2014;
Solleti et al. 2015). They also tend to induce type III secretion
system of the bacteria. Low concentration (2 μg/mL) of macrolides
enhances the production of some mutant strains e.g.
nfxB mutants, which then effectively produce the efflux pumps i.e.,
MexCD-OprJ. Chromosomally encoded expression of MexCD-OprJ and MexXY/MexAB-OprM
efflux pumps interferes with the natural resistance of P. aeruginosa against the macrolide (Mulet
et al. 2011).
Resistance
against chloramphenicol
Chloramphenicol is primarily bacteriostatic that
interferes with the multiplication of the microorganisms by binding to the 50S
subunit of the bacterial ribosomes and they inhibit the peptidaltransferase
enzyme. Pseudomonas is resistant
against chloramphenicol intrinsically, mainly due to the presence of an efflux
system of MexAB-oprM type (Fernández et al. 2012). Moreover, the sub-optimal doses of
the drug lead to the induction of MexXY efflux system.
Resistance
against fluoroquinolones
MexXY-OprM and MexAB-OprM contribute to quinolone
resistance in wild-type Pseudomonal
spp. (Morita et al. 2001). Efflux
pumps have been found that are responsible for the resistance development in
case of Pseudomonas i.e.,
MexVW-OprM and MexHI-OpmD. MexEF-OprN and MexCD-OprJ efflux pumps are linked to
quinolone resistance while MexCD-OprJ is related to multidrug resistance (Terzi et al. 2014).
Resistance
against other biocides
Triclosan, chlorhexidine and benzalkonium can become
contaminated with the Pseudomonas, therefore,
making the disinfectant less efficient (Shepherd
et al. 2018). Resistance
against triclosan is primarily due to an efflux pump i.e., MexAB-OprM (Mima et al. 2007; Zhu et al. 2010). The sub-optimal
concentration of the chlorhexidine and benzalkonium lead to the resistance
against Pseudomonas primarily by
MexCD-OprJ efflux pump. Pseudomonas
aeruginosa strains showing resistance against the benzalkonium also tend to
become resistant against the quinolones due to mutations in the gyrA, mexCD-oprJ and mexAB-oprM (Mc Cay et al. 2010).
Resistance mechanisms of P. aeruginosa have been summarized in Table 2.
Implications
of anti-microbial resistance in veterinary and public health and employing
alternative intervention strategies
In
humans, P. aeruginosa is known to
cause a myriad of clinical diseases such as sepsis, pneumonia, skin infections and cystic
fibrosis (Jeong et al. 2014). So,
these infections contribute significantly towards the higher morbidity,
mortality and treatment cost. According to China antimicrobial surveillance network
(CHINET), P. aeruginosa is one of the
four Gram-negative bacteria to be isolated from each clinical specimen (Hu et al. 2017). In animals, P. aeruginosa is known to cause many
diseases, including, chronic pyoderma, Urinary tract infections (UTIs), wound
infections, otitis externa, bovine mastitis and feline septicemia (Ahmad 2001; Mekić et al. 2011; Maniam et
al. 2019). P. aeruginosa
isolated from the cats and dogs in Japan have shown 4.1, 12.3, 17.8, 20.5, 31.5
and 34.2% resistance against gentamicin, aztreonam, cefotaxime, ciprofloxacin,
enrofloxacin and orbifloxacin. Ear Table
2: Resistance mechanisms of P. aeruginosa against commonly used
antimicrobials
Antimicrobial |
Mechanism |
Reference |
β- lactams |
Induction of AmpC β-
lactamase |
(Sahu et al. 2012) |
Aminoglycosides |
Expression of Heat shock genes; Alteration in MexXY–OprM |
(Islam et al. 2009; Basta et
al. 2020) |
|
Biofilm development |
(Linares et al. 2006) |
|
Induction of swimming and swarming |
(Linares et al. 2006) |
Carbapenems |
Development of thicker biofilm |
(Olivares et al. 2020) |
Chloramphenicol |
Induction of Mex EF-OprN
complex |
(Fernández et al. 2012) |
quinolones |
Over-expressed MexEF-OprN
and MexCD-OprJ |
(Terzi et al. 2014) |
Tetracycline |
Over-expressed mexA-mexB-oprM |
(Konai and Haldar 2020) |
MDR |
MexCD-OprJand MexAB-OprM |
(Terzi et al. 2014) |
isolates of P.
aeruginosa have shown resistance to orbifloxacin, enrofloxacin and
ciprofloxacin. Moreover, bacteria from urine were more resistant to many
antimicrobial drugs than skin isolates (Harada et
al. 2012). Similar findings have been demonstrated in a study that
showed that P. aeruginosa isolated
from canine otitis externa to be 47, 67 and 75% resistant against enrofloxacin,
marbofloxacin and ciprofloxacin (Wildermuth et
al. 2007). Similar trends of antimicrobial resistance have been
shown in the P. aeruginosa isolates
from mouth, skin, urogenital tract and ears (Werckenthin
et al. 2007). In the recent past, it has been demonstrated that P. aeruginosa can cross different
species barriers thereby indicating its potential as a zoonotic pathogen (Fernandes et al. 2018).
So, because of the
presence of multidrug resistance in P.
aeruginosa, there is a need for appropriate drug therapy to overcome this
issue, because inappropriate antimicrobial therapy at initial disease stages
can lead to enhanced morbidity and mortality. So, as done in the past, combinations
of antibiotics (although controversial) may be employed to deal with the
problem of multidrug resistance (Guan et al.
2016). Although colistin and amikacin exhibit anti-pseudomonal activity,
but their toxicity deters their frequent use in clinics. So, in this aspect,
new antibiotics that are known to possess activity against the multi-drug
resistance (MDR) P. aeruginosa, they
may be deployed prudently in clinics to curb the infection by MDR P. aeruginosa. Tazobactam/ Ceftolozane is a very effective antibacterial
drug combination that is recommended to treat the intra-abdominal infections as
well as UTIs. In vitro studies have demonstrated that the development of
antimicrobial resistance against this combination is slower as compared to the
other antibiotics (Tato et al. 2015).
Moreover, a new combination of avibactam (non beta-lactam)
with the 3rd generation cephalosporin (Ceftazidime) has also been
approved for the treatment of UTIs and intra-abdominal infections (along with
metronidazole) caused by P.
aeruginosa (Sader et al. 2017; Xipell
et al. 2017). Another study has also demonstrated that after
colistin, the combination of Tazobactam/Ceftolozane and avibactam/Ceftazidime was found to
be most effective against P.
aeruginosa infections where 97.5 and 96.9% of P.
aeruginosa population was found to be susceptible to both combinations,
respectively (Sader et al. 2018).
So, there is still much room to discover some novel antimicrobial combinations
which may prove good antimicrobial activity both in vitro and under clinics against P. aeruginosa.
Alternatively,
another approach to combat infections caused by P. aeruginosa may be by using various plant/herb
based compounds, and this approach is much safer than using
antimicrobials. Medicinal plants or herbs have a variety of compounds such as
long-chained unsaturated aldehydes, peptides, essential oils, and phenolic
compounds, which are known to possess the antimicrobial activity (Hameed and Ahmed 2014; Astal et al. 2005). It has been shown that ginseng
supplementation results in the reduced P.
aeruginosa and mast cells number in the lungs of rats, thereby
significantly reducing the lung pathology (Nguyen
and Nguyen 2019). Leave extract of Azadirachta indica (neem) are also found to inhibit the biofilms formation in P. aeruginosa (Harjai et al. 2013). One more study demonstrated that
flavonoids extracted from Moringa oleifera possess the anti-biofilm
activities of P. aeruginosa (Onsare and Arora 2015). Another study has
found that Zingiber officinale (ginger),
Glycyrrhiza glabra (liquorice) and Mentha
piperita (mint), possess antipseudomonal activity against many MDR strains (Chakotiya et al. 2016). Although the
exact mechanism by which these herbs/nutraceuticals impart antimicrobial
effects largely remains to be elucidated, however,
their phytochemicals play important role in the molecular mechanisms
involved in their antimicrobial effects. In
vivo mice model studies have shown that oral supplementation of garlic
extract is useful in preventing the infections caused by P. aeruginosa. After oral administration, garlic was found to be
effective in reducing the renal bacterial count. In vitro studies demonstrated the reduction in the signals
responsible for quorum sensing and thereby reducing the release of various
virulence factors (Harjai et al. 2010).
A more recent study also demonstrated that purified flavonoids fraction derived
from Cassia
alata L. (Ca. alata), was found to be associated with the reduced
release of virulence factors, reduction in quorum sensing signals and reduced
biofilm formation by P. aeruginosa
(Rekha et al. 2017). The latest
study has demonstrated that quercetin (natural flavonoid compound) has been
found to specifically inhibit the quorum sensing and thus biofilm formation and
virulence factors production by P.
aeruginosa (Ouyang et al. 2016).
Recently phage
therapy presented an alternative solution to multidrug-resistant bacteria and
it offers several advantages over antibiotics. A single dose of phage can
eradicate potentially infectious bacteria. However, till now, phages are
reported to be genera and species (even strain) specific (Nguyen et al. 2012). Siphoviridae phages
are known to be important in controlling P. aeruginosa infections(Yamaguchi et al.
2014). In a recent study, JHP phage has shown its antibacterial activity
against a myriad of P. aeruginosa strains
(Khawaja et al. 2016).
Conclusion
Resistance mechanisms are constantly evolving by natural
evolution or horizontal gene transfer. There is a grave challenge to tackle
infections these days as the antibiotic resistance keeps on increasing from
multidrug to pan-drug resistance. These resistant strains can be treated by
aggressive approach, avoiding the suboptimal doses. Infections should be
treated with broad-spectrum antibiotics followed by narrowing down to the
specific antibiotic till the sensitivity result comes. Antibiotic therapy can
be used with supporting agents as beta-lactamase inhibitors e.g.
Clavulanate or biofilm dissolving substances e.g., alginate lyases.
There is also need to focus on the post-antibiotic era; screening drugs for
efflux pump inhibitors, searching new types of beta-lactamase inhibitors,
exploring cationic membrane permeabilizers, manipulating medicinal
plants/herbs, enhancing quorum quenching to inhibit communication and biofilm
formation and phage therapy to treat infections. Emphasis should also be done
to improve the specific or general immune response of patients infected by P aeruginosa along with other
non-fermentative bacterial infections.
Author
Contributions
BEM and MAA conceived the idea, BEM
acquired the data, BEM and MAA wrote the manuscript with the inputs of MKB and
HB. MKB and HB worked on drafting and revising of the article critically.
Conflict of Interest
We declare that we do not have any conflict of interest.
Data Availability
Not applicable.
Ethics Approval
Not applicable.
Funding Source
The study did not receive any funding.
References
Ahmad R (2001). Studies on mastitis among dairy buffaloes. Pak Vet J
21:220‒221
Astal EZ, A Aera, K Aam (2005). Antimicrobial activity of some medicinal
plant extracts in Palestine. Pak J Med Sci 21:187‒193
Bagge N, O Ciofu, M Hentzer, JIA Campbell, M Givskov, N Hoiby (2002).
Constitutive high expression of chromosomal lactamase in Pseudomonas
aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob
Agents Chemother 46:3406‒3411
Baranova N (2016). Involvement of antimicrobial drug efflux systems in
bacterial fitness and virulence. In: Efflux-Mediated Antimicrobial Resistance in Bacteria, pp:701‒727. Adis, Cham,
Switzerland
Basta DW, D Angeles-Albores, MA Spero, JA Ciemniecki, DK Newman (2020).
Heat-shock proteases promote survival of Pseudomonas aeruginosa during
growth arrest. Proc Natl Acad Sci USA 117:4358‒4367
Breidenstein EBM, C de la Fuente-Núñez, REW Hancock (2011). Pseudomonas
aeruginosa: All roads lead to resistance. Trends Microbiol 19:419‒426
Buberg ML, IL Witsø, TM L’Abée-Lund, Y Wasteson (2020). Zinc and copper
reduce conjugative transfer of resistance plasmids from extended-spectrum
beta-lactamase-producing Escherichia coli.
Microb Drug Resist 26:842–849
Chakotiya AS, R Chawla, P Thakur, A Tanwar, A Narula, SS Grover, R Goel, R
Arora, RK Sharma (2016). In vitro
bactericidal activity of promising nutraceuticals for targeting multidrug
resistant Pseudomonas aeruginosa. Nutrition 32:890‒897
Chakraborty B, S Chatterjee, R Ray, N Pal, S Patra, P Maiti (2016).
Rethink on recommended concentrations of disinfectants in the light of biofilm,
based on in vitro study. Intl J
Heal Allied Sci 5:154-158
Daury L, F Orange, JC Taveau, A Verchère, L Monlezun, C Gounou, RKR
Marreddy, M Picard, I Broutin, KM Pos, O Lambert (2016). Tripartite assembly of
RND multidrug efflux pumps. Nat Commun 7; Article 10731
Dawson CC, C Intapa, MA Jabra-Rizk (2011). Persisters: Survival at the
cellular level. PLoS Pathog 7; Article e1002121
Du SJ, HC Kuo, CH Cheng, ACY Fei, HW Wei, SK Chang (2010). Molecular
mechanisms of ceftazidime resistance in Pseudomonas
aeruginosa isolates from canine and human infections. Vet Med 55:172‒182
Dunkle JA, K Vinal, PM Desai, N Zelinskaya, M Savic, DM West, GL Conn, CM
Dunham (2014). Molecular recognition and modification of the 30S ribosome by
the aminoglycoside-resistance methyltransferase NpmA. Proc Natl Acad Sci
111:6275‒6280
Fernandes MR, FP Sellera, Q Moura, MPN Carvalho, PN Rosato, L Cerdeira, N
Lincopan (2018). Zooanthroponotic transmission of drug-resistant Pseudomonas aeruginosa, Brazil. Emerg
Infect Dis 24:1160‒1162
Fernández M, S Conde, JDL Torre, C Molina-Santiago, JL Ramos, E Duque
(2012). Mechanisms of resistance to chloramphenicol in Pseudomonas putida
KT2440. Antimicrob Agents Chemother 56:1001‒1009
Ferstl P, N Filmann, C Brandt, S Zeuzem, T Wichelhaus, M Hogardt, V Kempf,
O Waidmann, C Reinheimer (2016). Colonization and infection with
carbapenem-resistant non-fermenting gram-negative bacteria are associated with
rapid deterioration and mortality in patients with decompensated liver disease.
Zeitsch Gastroenterol 54:KV268
Fluit AC, RJ Rentenaar, MB Ekkelenkamp, TT Severs, AMC Mavinkurve-Groothuis,
MRC Rogers, MCA Bruin, TFW Wolfs (2019). Fatal carbapenem resistance
development in Pseudomonas aeruginosa under meropenem monotherapy,
caused by mutations in the oprD outer membrane porin. Pediatr Infect Dis J
38:398‒399
Germoni LAP, PJ Bremer, IL Lamont (2016). The effect of alginate lyase on
the gentamicin resistance of Pseudomonas aeruginosa in mucoid biofilms. J
Appl Microbiol 121:126‒135
Guan X, L He, B Hu, J Hu, X Huang, G Lai, Y Li, Y Liu, Y Ni, H Qiu, Z
Shao, Y Shi, M Wang, R Wang, D Wu, C Xie, Y Xu, C Zhuo (2016). Laboratory
diagnosis, clinical management and infection control of the infections caused
by extensively drug-resistant Gram-negative Bacilli:
A Chinese consensus statement. Clin Microbiol Infect 22:15‒25
Hameed H, SI Ahmed (2014). The role of chemical and herbal antipathogenic
compounds in the prevention of quorum sensing-dependent pathogenicity of Pseudomonas
aeruginosa-A Review. Pak Vet J 34:426‒431
Hameed H, I Hussain, MS Mahmood, F Deeba, K Riaz (2017). Higher order
occurrence of virulent isolates of Pseudomonas aeruginosa in hospital
environments initiate one health concerns irrespective of the biological association.
Pak Vet J 37:7‒12
Harada K, S Arima, A Niina, Y Kataoka, T Takahashi (2012). Characterization
of Pseudomonas aeruginosa isolates from dogs and cats in Japan: Current
status of antimicrobial resistance and prevailing resistance mechanisms. Microbiol
Immunol 56:123‒127
Harjai K, A Bala, RK Gupta, R Sharma (2013). Leaf extract of Azadirachta
indica (neem): A potential antibiofilm agent for Pseudomonas aeruginosa.
Pathog Dis 69:62–65
Harjai K, R Kumar, S Singh (2010). Garlic blocks quorum sensing and
attenuates the virulence of Pseudomonas aeruginosa. FEMS Immunol Med
Microbiol 58:161‒168
Hu F, Y Guo, D Zhu, F Wang, X Jiang, Y Xu, X Zhang, Z Zhang, P Ji, Y Xie,
M Kang, C Wang, A Wang, Y Xu, J Shen, Z Sun, Z Chen, J Meng (2017). CHINET
surveillance of bacterial resistance across China: Report of the results in
2016. Chin J Infect Chemother 17:481‒491
Islam S, H Oh, S Jalal, F Karpati, O Ciofu, N Høiby, B Wretlind (2009).
Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas
aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infect
15:60‒66
Jeong J, Y Cho, H Lee, M Kim, N Kim, H Song, K Lee (2014). Multifocal
discospondylitis in a male dog with prostatic abscess and cystitis. Pak Vet
J 34:566‒568
Kao CY, SS Chen, KH Hung, HM Wu, PR Hsueh, JJ Yan, JJ Wu (2016).
Overproduction of active efflux pump and variations of OprD dominate in
imipenem-resistant Pseudomonas aeruginosa isolated from patients with
bloodstream infections in Taiwan. BMC Microbiol 16; Article 107
Khalil MAEF, FI Sonbol, AFB Mohamed, SS Ali (2015). Comparative study of
virulence factors among ESβL-producing and nonproducing Pseudomonas
aeruginosa clinical isolates. Turk J Med Sci 45:60‒69
Khawaja KA, M Rauf, Z Abbas, S ur Rehman (2016). A virulent phage JHP
against Pseudomonas aeruginosa showed infectivity against multiple
genera. J Basic Microbiol 56:1090‒1097
Konai MM, J Haldar (2020). Lysine-based small molecule sensitizes
rifampicin and tetracycline against multidrug-resistant Acinetobacter
baumannii and Pseudomonas aeruginosa. ACS Infect Dis 6:91‒99
Kondo S, K Hotta (1999). Semisynthetic aminoglycoside antibiotics:
Development and enzymatic modifications. J Infect Chemother 5:1‒9
Krahn T, C Gilmour, J Tilak, S Fraud, N Kerr, CH-F Lau, K Poole (2012).
Determinants of intrinsic aminoglycoside resistance in Pseudomonas
aeruginosa. Antimicrob Agents Chemother 56:5591‒5602
Laserna E, O Sibila, JF Fernandez, DJ Maselli, EM Mortensen, A Anzueto, G
Waterer, MI Restrepo (2014). Impact of macrolide therapy in patients
hospitalized with Pseudomonas aeruginosa community-acquired pneumonia. Chest
145:1114‒1120
Linares JF, I Gustafsson, F Baquero, JL Martinez, GIBFMJ Linares JF
(2006). Antibiotics as intermicrobial signaling agents instead of weapons. Proc
Natl Acad Sci USA 103:19484‒19489
Maniam R, A Salleh, ZS Mohd, J Faez, F Abdullah, Z Zunita (2019). A study
of aetiology and risk factors of bacterial septicaemia of cats. Pak Vet J
39:236‒240
Manohar P, S Babu, B Bozdogan, N Ramesh (2018). Identification of blaDIM-1
metallo-β-lactamase gene in Pseudomonas aeruginosa isolated from
Tamil Nadu, India. J Glob Antimicrob Resist 13:7‒8
Mc Cay PH, AA Ocampo-Sosa, GTA Fleming (2010). Effect of subinhibitory
concentrations of benzalkonium chloride on the competitiveness of Pseudomonas
aeruginosa grown in continuous culture. Microbiology 156:30‒38
Mekić S, K Matanović, B Šeol (2011). Antimicrobial
susceptibility of Pseudomonas aeruginosa isolates from dogs with otitis
externa. Vet Rec 169:125–129
Mima T, S Joshi, M Gomez-Escalada, HP Schweizer (2007). Identification and
characterization of TriABC-OpmH, a triclosan efflux pump of Pseudomonas
aeruginosa requiring two membrane fusion proteins. J Bacteriol
189:7600‒7609
Morita Y, J Tomida, Y Kawamura (2012). MexXY multidrug efflux system of Pseudomonas
aeruginosa. Front Microbiol 3; Article 408
Morita Y, N Kimura, T Mima, T Mizushima, T Tsuchiya (2001). Roles of
MexXY- and MexAB-multidrug efflux pumps in intrinsic multidrug resistance of Pseudomonas
aeruginosa PAO1. J Gen Appl Microbiol 47:27‒32
Mulet X, B Moyá, C Juan, MD Macià, JL Pérez, J Blázquez, A Oliver (2011).
Antagonistic interactions of Pseudomonas aeruginosa antibiotic
resistance mechanisms in planktonic but not biofilm growth. Antimicrob
Agents Chemother 55:4560‒4568
Nguyen NH, CT Nguyen (2019). Pharmacological effects of ginseng on
infectious diseases. Inflammopharmacology 27:871‒883
Nguyen HTD, S Yoon, MH Kim, YK Kim, MY Yoon, YH Cho, Y Lim, SH Shin, DE Kim
(2012). Characterization of bacteriophage ϕPto-bp6g, a novel phage that
lyses Pseudomonas tolaasii causing brown blotch disease in mushrooms. J
Microbiol Meth 91:514‒519
Olivares E, S Badel-Berchoux, C Provot, G Prévost, T Bernardi, F Jehl
(2020). Clinical impact of antibiotics for the treatment of Pseudomonas aeruginosa biofilm infections.
Front Microbiol 10; Article 2894
Onsare JG, DS Arora (2015). Antibiofilm potential of flavonoids extracted
from Moringa oleifera seed coat against Staphylococcus aureus, Pseudomonas
aeruginosa and Candida albicans. J Appl Microbiol 118:313‒325
Ouyang J, F Sun, W Feng, Y Sun, X Qiu, L Xiong, Y Liu, Y Chen (2016).
Quercetin is an effective inhibitor of quorum sensing, biofilm formation and
virulence factors in Pseudomonas aeruginosa. J Appl Microbiol
120:966‒974
Park Y, J Oh, S Park, S Sum, W Song, J Chae, H Park (2020). Antimicrobial
resistance and novel mutations detected in the gyrA and parC genes of Pseudomonas
aeruginosa strains isolated from companion dogs. BMC Vet Res 16;
Article 111
Qadi M, C Lopez-Causapé, S Izquierdo-Rabassa, M Mateu Borrás, JB Goldberg,
A Oliver, S Albertí (2016). Surfactant protein A recognizes outer membrane
protein OprH on Pseudomonas aeruginosa
chronic infection isolates. J Infect Dis 214:1449‒1455
Rekha PD, HS Vasavi, C Vipin, K Saptami, AB Arun (2017). A medicinal herb Cassia
alata attenuates quorum sensing in Chromobacterium violaceum and Pseudomonas
aeruginosa. Lett Appl Microbiol 64:231‒238
Richardot C, P Plésiat, D Fournier, L Monlezun, I Broutin, C Llanes
(2015). Carbapenem resistance in cystic fibrosis strains of Pseudomonas
aeruginosa as a result of amino acid substitutions in porin OprD. Intl J
Antimicrob Agents 45:529‒532
Rostami S, A Farajzadeh Sheikh, S Shoja, A Farahani, MA Tabatabaiefar, A
Jolodar, R Sheikhi (2018). Investigating of four main carbapenem-resistance
mechanisms in high-level carbapenem resistant Pseudomonas aeruginosa
isolated from burn patients. J Chin Med Assoc 81:127‒132
Sader HS, RK Flamm, CG Carvalhaes, M Castanheira (2018).
Antimicrobial susceptibility of Pseudomonas aeruginosa to
ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and
meropenem stratified by U.S. census divisions: Results from the 2017 INFORM
program. Antimicrob Agents Chemother 62:1-6
Sader HS, M Castanheira, D Shortridge, RE Mendes, RK Flamm (2017).
Antimicrobial activity of ceftazidime-avibactam tested against
multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa
isolates from U.S. Medical Centers, 2013 to 2016. Antimicrob Agents
Chemother 61; Article e01045-17
Sahu MC, D Dubey, S Rath, NK Debata, RN Padhy (2012). Multidrug resistance
of Pseudomonas aeruginosa as known from surveillance of nosocomial and
community infections in an Indian teaching hospital. J Public Health
20:413‒423
Shepherd MJ, G Moore, ME Wand, JM Sutton, LJ Bock (2018). Pseudomonas
aeruginosa adapts to octenidine in the laboratory and a simulated clinical
setting, leading to increased tolerance to chlorhexidine and other biocides. J
Hosp Infect 100:e23–e29
Solleti VS, M Alhariri, M Halwani, A Omri (2015). Antimicrobial properties
of liposomal azithromycin for Pseudomonas infections in cystic fibrosis
patients. J Antimicrob Chemother 70:784‒796
Song J, JCE Odekerken, DWPM Löwik, PM López-Pérez, TJM Welting, F Yang, JA
Jansen, SCG Leeuwenburgh (2015). Influence of the molecular weight and charge
of antibiotics on their release kinetics from gelatin nanospheres. Macromol
Biosci 15:901‒911
Tato M, M García-Castillo, AM Bofarull, R Cantón (2015). In vitro activity
of ceftolozane/tazobactam against clinical isolates of Pseudomonas
aeruginosa and Enterobacteriaceae recovered in Spanish medical centres:
Results of the CENIT study. Intl J Antimicrob Agents 46:502‒510
Terzi HA, C Kulah, IH Ciftci (2014). The effects of active efflux pumps on
antibiotic resistance in Pseudomonas aeruginosa. World J Microbiol
Biotechnol 30:2681‒2687
van ‘t Wout EFA, A van Schadewijk, R van Boxtel, LE Dalton, HJ Clarke, J
Tommassen, SJ Marciniak, PS Hiemstra (2015). Virulence factors of Pseudomonas
aeruginosa induce both the unfolded protein and integrated stress responses
in airway epithelial cells. PLOS Pathog 11; Article e1004946
Werckenthin C, E Alesík, M Grobbel, A Lübke-Becker, S
Schwarz, L Wieler, J Wallmann (2007). Antimicrobial susceptibility of Pseudomonas
aeruginosa from dogs and cats as well as Arcanobacterium pyogenes
from cattle and swine as determined in the BfT-GermVet monitoring program 2004–2006.
Berl Munch Tierarztl Wochenschr 120:412‒422
Wildermuth BE, CE Griffin, WS Rosenkrantz, MJ Boord (2007).
Susceptibility of Pseudomonas isolates from the ears and skin of dogs to
enrofloxacin, marbofloxacin, and ciprofloxacin. J Amer Anim Hosp Assoc
43:337‒341
Xipell M, M Bodro, F Marco, RA Losno, C Cardozo, A Soriano
(2017). Clinical experience with ceftazidime/avibactam in patients with severe
infections, including meningitis and lung abscesses, caused by extensively
drug-resistant Pseudomonas aeruginosa. Intl J Antimicrob Agents
49:266‒268
Xu Y, H Niu, T Hu, L Zhang, S Su, H He, H Wang, D Zhang
(2020). High expression of metallo-β-lactamase contributed to the
resistance to carbapenem in clinical isolates of Pseudomonas aeruginosa
from Baotou, China. Infect Drug Resist 13:35‒43
Yamaguchi K, R Miyata, R Shigehisa, J Uchiyama, I
Takemura-Uchiyama, SI Kato, T Ujihara, Y Sakaguchi, M Daibata, S Matsuzaki
(2014). Genome analysis of Pseudomonas
aeruginosa bacteriophage KPP23, belonging to the family Siphoviridae. Genome
Announc 2; Article e00233-14
Zhu L, J Lin, J Ma, JE Cronan, H Wang
(2010). Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to
FabV, a triclosan-resistant enoyl-acyl carrier protein reductase. Antimicrob
Agents Chemother 54:689‒698